Summit Therapeutics appoints Dr. Mostafa Ronaghi to board of directors

Summit Therapeutics Inc.

Dr. Ronaghi elected to board and Compensation Committee effective April 11, 2024.
Received option grant per non-employee director compensation policy; indemnification agreement.
Former CTO and SVP at Illumina (2008-2021); co-founded GRAIL in 2016.
Summit CEO cites Ronaghi's expertise in genomics to help maximize ivonescimab potential.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mostafa Ronaghi

Director

SMMT · Summit Therapeutics Inc.

Effective: 2024-04-11
Filed: April 11, 2024, 7:59 PM ET

the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved the election of Mostafa Ronaghi, PhD, as a director of the Company and the appointment of Dr. Ronaghi to serve on the Compensation Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mostafa Ronaghi was appointed as Director at Summit Therapeutics Inc..

Action: appointed
Role: Director

Exact text from the filing

the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved the election of Mostafa Ronaghi, PhD, as a director of the Company and the appointment of Dr. Ronaghi to serve on the Compensation Committee of the Board.

View on SEC.gov

Summit Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001599298-24-000064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.